World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
137
Citations
80338
World Ranking
1890
National Ranking
1072

Overview

Elihu H. Estey is affiliated with the University of Washington in the United States and has a research focus primarily in the field of Medicine. Their work spans several subfields, including Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology, and Molecular Biology.

The scientist has contributed extensively to several main topics of study, such as:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Neutropenia and Cancer Infections
  • Chronic Myeloid Leukemia Treatments
  • Hematopoietic Stem Cell Transplantation
  • Hematological Disorders and Diagnostics

Among recent papers authored by or including Estey are:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data (2022, Blood)
  • Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal (2021, Blood)
  • Acute myeloid leukemia: 2021 update on risk-stratification and management (2020, American Journal of Hematology)
  • CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia (2020, Journal of Clinical Investigation)
  • Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? (2020, Leukemia)

The scientist frequently publishes in prominent venues including:

  • Blood
  • Leukemia & lymphoma / Leukemia and lymphoma
  • Leukemia
  • American Journal of Hematology
  • Blood Advances

Elihu H. Estey collaborates frequently with other researchers in the field. Notable co-authors include:

  • Roland B. Walter
  • Mary-Elizabeth M. Percival
  • Anna B. Halpern
  • Megan Othus
  • Pamela S. Becker

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

    Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum

  • Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  • Acute myeloid leukaemia

    Elihu Estey;Hartmut Döhner

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

    Eric L. Sievers;Richard A. Larson;Edward A. Stadtmauer;Elihu Estey

  • Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

    Zekaver Odabasi;Gloria Mattiuzzi;Elihu Estey;Hagop Kantarjian

  • Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials

    Robert Kerrin Hills;Sylvie Castaigne;Frederick R. Appelbaum;Jacques Delaunay

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

    Zhihong Zeng;Yue Xi Shi;Ismael J. Samudio;Rui Yu Wang

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

    Richard A. Larson;Eric L. Sievers;Eric L. Sievers;Edward A. Stadtmauer;Bob Löwenberg

  • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

    Andres O. Soriano;Hui Yang;Stefan Faderl;Zeev Estrov

  • Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

    Miguel A. Sanz;Miguel A. Sanz;Pierre Fenaux;Martin S. Tallman;Elihu H. Estey

  • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

    Alvaro Aguayo;Elihu Estey;Elihu Estey;Hagop M Kantarjian;Hagop M Kantarjian;Taghi Mansouri;Taghi Mansouri

  • JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia

    Jaroslav Jelinek;Yasuhiro Oki;Vazganush Gharibyan;Vazganush Gharibyan;Vazganush Gharibyan;Carlos Bueso-Ramos

  • The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

    Ross L. Levine;Marc Loriaux;Brian J. P. Huntly;Mignon L. Loh

  • Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

    Roland B. Walter;Ted A. Gooley;Brent L. Wood;Filippo Milano

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Susan O'Brien
Susan O'Brien University of California, Irvine
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Francis J. Giles
Francis J. Giles Northwestern University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Miloslav Beran
Miloslav Beran The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean following the traditional path to becoming a doctor. Many students are exploring alternative online degrees and career pathways that play key roles within the healthcare system. These online options offer flexibility, affordability, and faster entry into the workforce.

Programs such as medical billing and coding online schools prepare you for crucial behind-the-scenes positions that support healthcare providers. For aspiring nurses seeking fewer barriers to entry, choosing a nursing school that doesn't require teas can save time and reduce stress during the application process.

If you’re interested in leadership roles, consider the healthcare administration programs available online, many of which are accelerated for working professionals. Nurses looking to advance their careers can bridge the gap from an associate’s degree to a nurse practitioner qualification via adn to np programs online.

These online pathways provide diverse opportunities and help meet the growing demand for qualified healthcare professionals across the United States.

Best Scientists Citing Elihu H. Estey

Trending Scientists